Mitsubishi UFJ Trust & Banking
SRPT icon

Mitsubishi UFJ Trust & Banking’s Sarepta Therapeutics SRPT Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Sell
23,528
-26,277
-53% -$497K ﹤0.01% 1119
2026
Q1 		$1.08M Buy
49,805
+8,483
+21% +$164K ﹤0.01% 894
2025
Q4 		$889K Buy
41,322
+18,381
+80% +$387K ﹤0.01% 904
2025
Q3 		$442K Buy
+22,941
New +$409K ﹤0.01% 983
2021
Q2 		– Sell
-43,769
Closed -$3.31M – 1395
2021
Q1 		$3.31M Sell
43,769
-11,223
-20% -$1.04M 0.01% 752
2020
Q4 		$9.38M Sell
54,992
-1,889
-3% -$280K 0.02% 641
2020
Q3 		$7.99M Sell
56,881
-1,516
-3% -$230K 0.02% 614
2020
Q2 		$9.36M Buy
58,397
+355
+0.6% +$48.3K 0.02% 566
2020
Q1 		$5.68M Buy
58,042
+3,611
+7% +$413K 0.02% 629
2019
Q4 		$7.02M Sell
54,431
-1,382
-2% -$139K 0.02% 681
2019
Q3 		$4.2M Buy
+55,813
New +$6.59M 0.01% 738

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's SRPT Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking reduced its Sarepta Therapeutics (SRPT) stake by 53% in Q2 2026, selling an estimated $497K and leaving 23,528 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Mitsubishi UFJ Trust & Banking first reported a position in SRPT in Q3 2019 and has held it in 11 quarters since. The position peaked at $9.38M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 23,528 shares of Sarepta Therapeutics worth $423K as of Q2 2026.
  • Mitsubishi UFJ Trust & Banking sold 26,277 Sarepta Therapeutics shares in Q2 2026, an estimated $497K.
  • Sarepta Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1119 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in Sarepta Therapeutics in Q3 2019 and has held it in 11 quarters since.
  • Mitsubishi UFJ Trust & Banking's Sarepta Therapeutics position peaked at $9.38M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.